These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17229244)

  • 1. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.
    Ratziu V; Giral P; Munteanu M; Messous D; Mercadier A; Bernard M; Morra R; Imbert-Bismut F; Bruckert E; Poynard T
    Aliment Pharmacol Ther; 2007 Jan; 25(2):207-18. PubMed ID: 17229244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.
    Imbert-Bismut F; Naveau S; Morra R; Munteanu M; Ratziu V; Abella A; Messous D; Thabut D; Benhamou Y; Poynard T
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):18-27. PubMed ID: 19011575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.
    Jacqueminet S; Lebray P; Morra R; Munteanu M; Devers L; Messous D; Bernard M; Hartemann-Heurtier A; Imbert-Bismut F; Ratziu V; Grimaldi A; Poynard T
    Clin Gastroenterol Hepatol; 2008 Jul; 6(7):828-31. PubMed ID: 18524692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FibroMAX: towards a new universal biomarker of liver disease?
    Morra R; Munteanu M; Imbert-Bismut F; Messous D; Ratziu V; Poynard T
    Expert Rev Mol Diagn; 2007 Sep; 7(5):481-90. PubMed ID: 17892356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver biopsy versus noninvasive methods--fibroscan and fibrotest in the diagnosis of non-alcoholic fatty liver disease: a review of the literature.
    Pais R; Lupşor M; Poantă L; Silaghi A; Rusu ML; Badea R; Dumitraşcu DL
    Rom J Intern Med; 2009; 47(4):331-40. PubMed ID: 21179914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease.
    Naveau S; Gaudé G; Asnacios A; Agostini H; Abella A; Barri-Ova N; Dauvois B; Prévot S; Ngo Y; Munteanu M; Balian A; Njiké-Nakseu M; Perlemuter G; Poynard T
    Hepatology; 2009 Jan; 49(1):97-105. PubMed ID: 19053048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease in severely obese subjects.
    Gholam PM; Flancbaum L; Machan JT; Charney DA; Kotler DP
    Am J Gastroenterol; 2007 Feb; 102(2):399-408. PubMed ID: 17311652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic disturbances in non-alcoholic fatty liver disease.
    Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
    Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery.
    Trak-Smayra V; Dargere D; Noun R; Albuquerque M; Yaghi C; Gannagé-Yared MH; Bedossa P; Paradis V
    Gut; 2009 Jun; 58(6):825-32. PubMed ID: 18403495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease.
    Lydatakis H; Hager IP; Kostadelou E; Mpousmpoulas S; Pappas S; Diamantis I
    Liver Int; 2006 Sep; 26(7):864-71. PubMed ID: 16911470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience.
    Munteanu M; Ratziu V; Morra R; Messous D; Imbert-Bismut F; Poynard T
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):187-91. PubMed ID: 18568141
    [No Abstract]   [Full Text] [Related]  

  • 12. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.
    Lassailly G; Caiazzo R; Hollebecque A; Buob D; Leteurtre E; Arnalsteen L; Louvet A; Pigeyre M; Raverdy V; Verkindt H; Six MF; Eberle C; Patrice A; Dharancy S; Romon M; Pattou F; Mathurin P
    Eur J Gastroenterol Hepatol; 2011 Jun; 23(6):499-506. PubMed ID: 21499110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive assessment of chronic liver and gastric diseases.
    Plebani M; Basso D
    Clin Chim Acta; 2007 May; 381(1):39-49. PubMed ID: 17374528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
    Ito S; Yukawa T; Uetake S; Yamauchi M
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy.
    Lindsay K; Fraser AD; Layton A; Goodfield M; Gruss H; Gough A
    Rheumatology (Oxford); 2009 May; 48(5):569-72. PubMed ID: 19273538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity.
    Tsochatzis E; Papatheodoridis GV; Hadziyannis E; Georgiou A; Kafiri G; Tiniakos DG; Manesis EK; Archimandritis AJ
    Scand J Gastroenterol; 2008; 43(9):1128-36. PubMed ID: 18609175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests.
    Nguyen-Khac E; Chatelain D; Tramier B; Decrombecque C; Robert B; Joly JP; Brevet M; Grignon P; Lion S; Le Page L; Dupas JL
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1188-98. PubMed ID: 18705692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test.
    Gudowska M; Wojtowicz E; Cylwik B; Gruszewska E; Chrostek L
    Adv Clin Exp Med; 2015; 24(5):823-7. PubMed ID: 26768633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between the Fibrotest and portal hypertension in patients with liver disease.
    Thabut D; Imbert-Bismut F; Cazals-Hatem D; Messous D; Muntenau M; Valla DC; Moreau R; Poynard T; Lebrec D
    Aliment Pharmacol Ther; 2007 Aug; 26(3):359-68. PubMed ID: 17635370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.